GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BUE:GILD) » Definitions » Cyclically Adjusted Book per Share

Gilead Sciences (BUE:GILD) Cyclically Adjusted Book per Share : ARS6,125.30 (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Gilead Sciences Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Gilead Sciences's adjusted book value per share for the three months ended in Mar. 2025 was ARS16,407.550. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is ARS6,125.30 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Gilead Sciences's average Cyclically Adjusted Book Growth Rate was 3.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 8.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 11.10% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 16.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Gilead Sciences was 29.80% per year. The lowest was 2.40% per year. And the median was 23.95% per year.

As of today (2025-05-13), Gilead Sciences's current stock price is ARS30000.00. Gilead Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was ARS6,125.30. Gilead Sciences's Cyclically Adjusted PB Ratio of today is 4.90.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Gilead Sciences was 27.10. The lowest was 3.56. And the median was 6.05.


Gilead Sciences Cyclically Adjusted Book per Share Historical Data

The historical data trend for Gilead Sciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Cyclically Adjusted Book per Share Chart

Gilead Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 434.31 733.78 1,372.09 4,307.38 5,406.43

Gilead Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,860.09 6,145.58 5,675.10 5,406.43 6,125.30

Competitive Comparison of Gilead Sciences's Cyclically Adjusted Book per Share

For the Drug Manufacturers - General subindustry, Gilead Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Cyclically Adjusted PB Ratio falls into.


;
;

Gilead Sciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gilead Sciences's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book= Book Value per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=16407.55/134.9266*134.9266
=16,407.550

Current CPI (Mar. 2025) = 134.9266.

Gilead Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201506 100.470 100.684 134.640
201509 112.996 100.392 151.867
201512 168.696 99.792 228.089
201603 145.152 100.470 194.932
201606 163.177 101.688 216.514
201609 190.330 101.861 252.114
201612 228.554 101.863 302.741
201703 241.116 102.862 316.277
201706 286.293 103.349 373.768
201709 333.107 104.136 431.601
201712 298.425 104.011 387.127
201803 319.145 105.290 408.979
201806 417.052 106.317 529.280
201809 650.125 106.507 823.602
201812 629.015 105.998 800.684
201903 673.520 107.251 847.323
201906 797.865 108.070 996.148
201909 910.189 108.329 1,133.660
201912 1,063.507 108.420 1,323.513
202003 1,092.251 108.902 1,353.275
202006 984.153 108.767 1,220.849
202009 1,033.613 109.815 1,269.972
202012 1,181.243 109.897 1,450.280
202103 1,361.400 111.754 1,643.685
202106 1,488.409 114.631 1,751.928
202109 1,672.778 115.734 1,950.176
202112 1,696.777 117.630 1,946.283
202203 1,704.863 121.301 1,896.368
202206 1,941.785 125.017 2,095.706
202209 2,335.889 125.227 2,516.828
202212 2,855.562 125.222 3,076.871
202303 3,323.684 127.348 3,521.485
202306 4,071.917 128.729 4,267.968
202309 6,261.776 129.860 6,506.110
202312 6,615.117 129.419 6,896.611
202403 11,850.020 131.776 12,133.321
202406 13,140.102 132.554 13,375.318
202409 14,092.726 133.029 14,293.763
202412 15,665.436 133.157 15,873.611
202503 16,407.550 134.927 16,407.550

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Gilead Sciences  (BUE:GILD) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Gilead Sciences's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=30000.00/6125.30
=4.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Gilead Sciences was 27.10. The lowest was 3.56. And the median was 6.05.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Gilead Sciences Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences Business Description

Industry
Address
333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).